450-29-3 Usage
General Description
4-(4-fluoro-phenyl)-2-methyl-thiazole is a chemical compound that belongs to the thiazole family. It is characterized by a thiazole ring with a 4-(4-fluoro-phenyl) group attached at position 4 and a methyl group at position 2. 4-(4-FLUORO-PHENYL)-2-METHYL-THIAZOLE is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It is known for its diverse biological activities, including antimicrobial, antifungal, and antitumor properties. Due to its potential as a pharmacological agent, 4-(4-fluoro-phenyl)-2-methyl-thiazole is a subject of interest in medicinal chemistry research. Additionally, its unique chemical structure makes it a valuable tool for the development of new molecules with improved properties.
Check Digit Verification of cas no
The CAS Registry Mumber 450-29-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,5 and 0 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 450-29:
(5*4)+(4*5)+(3*0)+(2*2)+(1*9)=53
53 % 10 = 3
So 450-29-3 is a valid CAS Registry Number.
InChI:InChI=1/C10H8FNS/c1-7-12-10(6-13-7)8-2-4-9(11)5-3-8/h2-6H,1H3
450-29-3Relevant articles and documents
Access to Thiazole via Copper-Catalyzed [3+1+1]-Type Condensation Reaction under Redox-Neutral Conditions
Tang, Xiaodong,Yang, Jidan,Zhu, Zhongzhi,Zheng, Meifang,Wu, Wanqing,Jiang, Huanfeng
, p. 11461 - 11466 (2016/11/28)
A new strategy for thiazoles via copper-catalyzed [3+1+1]-type condensation reaction from oximes, anhydrides and potassiumthiocyanate (KSCN) is developed herein. The transformation has good functional group tolerance and various thiazoles were formed smoothly in good to excellent yields under mild reaction conditions. This process involves copper-catalyzed N-O/C-S bond cleavages, activation of vinyl sp2 C-H bond, and C-S/C-N bond formations which are under redox-neutral conditions as well as operational simplicity.
KINASE INHIBITORS
-
Page/Page column 27, (2010/02/13)
The present invention provides kinase inhibitors of Formula I.
